Peer-reviewed literature reviews on every compound we carry. Written in research language. No health claims. No dosing guidance. Just the published science, cited and honest.
Literature review — in-vitro and animal model findings
Literature overview — Thymosin Beta-4 analog studies
Biochemistry overview — copper peptide complex research
Coenzyme pathways — cellular biochemistry literature
FDA guidance overview — research chemical classification
A literature review of published preclinical research. This article does not constitute medical advice and makes no claims regarding human application.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice. The compound has been the subject of significant preclinical research interest, particularly in in-vitro cell culture models and rodent studies. The following summarizes key findings from published peer-reviewed research. This is not a clinical summary and does not reflect any approved human application.
Preclinical research published in peer-reviewed journals has examined BPC-157 in the context of several biological systems. Sikiric et al. (2018) documented activity in rodent models related to the nitric oxide signaling pathway, noting measurable changes in NO synthesis markers in tissue samples. The research was conducted in controlled animal model conditions and has not been replicated in human trials.
A 2020 review by Vukojevic et al. examined BPC-157 activity in various rodent tissue models, describing observed angiogenesis-related signaling in controlled laboratory settings. The authors noted limitations of extrapolating animal model data to human physiology and called for further controlled studies before any conclusions regarding human application could be drawn.
As of the FDA’s 2024 guidance on bulk drug substances, BPC-157 was classified as a Category II compound, indicating it may not be used in compounding for human use under current federal guidance. Researchers should consult current FDA guidance documents and applicable state regulations before any research involving this compound. See our Regulatory Overview article for additional context.
A literature overview of published preclinical research on the Thymosin Beta-4 synthetic analog. No health claims. No human use guidance.
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in virtually all human and animal cells. Thymosin Beta-4 has been studied in preclinical research contexts for its role in actin sequestration and cytoskeletal dynamics. TB-500 represents a synthetic version of the active region of Tβ4. The following is a summary of published research findings in preclinical models only.
Goldstein et al. (2012) reviewed the biology of Thymosin Beta-4 in the context of cellular research, noting its role as a major actin-sequestering molecule in eukaryotic cells and describing its involvement in cell migration and differentiation pathways observed in controlled laboratory conditions.
An overview of published biochemistry and preclinical research on the copper peptide GHK-Cu. No therapeutic claims.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Plasma concentrations decline with age, making it an active area of preclinical biological research. The following summarizes key published findings in laboratory and preclinical contexts.
Pickart et al. (2015) published an extensive review of GHK-Cu in the context of gene expression research, documenting observed effects on gene regulation in cell culture models. The researchers noted significant upregulation of genes associated with collagen synthesis and antioxidant enzyme expression in controlled in-vitro settings. The authors were explicit that these findings are preclinical and require further study before any conclusions regarding human biology can be drawn.
A summary of the biochemical role of Nicotinamide Adenine Dinucleotide in cellular research literature. No health claims. No therapeutic guidance.
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in all living cells, central to cellular respiration and metabolic processes. It serves as an electron carrier in redox reactions and is a substrate for several enzyme classes including sirtuins and PARPs. NAD+ has been the subject of extensive biochemistry research and is one of the most well-documented coenzymes in cellular biology literature.
Verdin (2015) published a landmark review in Science examining NAD+ metabolism in the context of aging research, documenting observed NAD+ concentration changes in aging cell models and the relationship to sirtuin enzyme activity in controlled laboratory conditions. This research is frequently cited in cellular biology contexts and represents foundational preclinical literature in the field.
An overview of current FDA guidance relevant to research peptide procurement and use. Not legal advice. Consult qualified regulatory counsel for your specific situation.
The regulatory environment for research peptides and biological compounds has undergone significant change since 2023. The FDA’s 2024 guidance on bulk drug substances used in compounding established formal Category I and Category II classifications for numerous compounds previously sold as research chemicals. Researchers and suppliers operating in this space should be aware of the following key developments.
Under the FDA’s guidance, bulk drug substances are classified into categories that determine their eligibility for use in compounding for human administration. Category I compounds may be used in compounding; Category II compounds may not. Several peptides commonly sold as research chemicals — including BPC-157 and TB-500 — were classified as Category II in 2024 guidance documents.
Importantly, Category II classification relates specifically to compounding for human use. Legitimate research use in controlled laboratory settings under institutional oversight is governed by separate regulations and institutional review requirements.
Researchers working with peptide compounds in institutional settings should consult with their institution’s regulatory affairs office and review current FDA guidance documents. Individual researchers should consult qualified regulatory counsel regarding their specific research context, jurisdiction, and institutional status.
This article is provided for general informational purposes only. It does not constitute legal advice, regulatory guidance, or a representation of what is permissible in any specific jurisdiction or research context. Double Helix Labs, LLC is a research chemical supplier, not a law firm or regulatory agency. Researchers are responsible for their own compliance with all applicable federal, state, and institutional regulations.